130 results on '"Voon, Pei Jye"'
Search Results
2. Identification of phenomic data in the pathogenesis of cancers of the gastrointestinal (GI) tract in the UK biobank
3. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia
4. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
5. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
6. Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
7. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
8. International Collaboration on Palliative Care Development Between ASCO and the Land of Hornbills
9. To refer or not? Oncology and palliative care
10. Barriers And Challenges Of Multidisciplinary Teams In Oncology Management: A Scoping Review Protocol
11. Gaps in cancer care in a multi-ethnic population in Sarawak, Borneo: A central referral centre study.
12. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
13. Malaysian Patient Perspectives on Clinical Trial Participation: Willingness, Knowledge, Perceptions, Confidence, and Religious Barriers
14. Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in Malaysia
15. Development and validation of Join Clinical Trial Questionnaire (JoinCT)
16. A 4-year review of surgical and oncological outcomes of endoscopic endonasal transpterygoid nasopharyngectomy in salvaging locally recurrent nasopharyngeal carcinoma
17. Identification of phenomic data in the pathogenesis of cancers of the gastrointestinal (GI) tract: A UK biobank data analysis
18. Peripheral transbronchial needle aspiration-guided pinpoint cryobiopsy of lung nodule without bronchus sign: A case report
19. A new era of the Asian clinical research network: a report from the ATLAS international symposium
20. Molecular pathology quality control in Southeast Asia: Results of a multiregional quality assurance study from MASTER KEY Asia
21. Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset
22. Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
23. Early phase oncology clinical trials in Malaysia: current status and future perspectives
24. Early phase oncology clinical trials in Malaysia: current status and future perspectives
25. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
26. Early phase oncology clinical trials in Malaysia: current status and future perspectives.
27. A randomized study to measure and enhance the health-related quality of life in patients with cancer receiving immune checkpoint modulators (ME-Q).
28. Additional file 2 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
29. Additional file 1 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
30. Additional file 3 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
31. Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)
32. Phase I Pharmacokinetic Study of Single Agent Trametinib in Patients With Advanced Cancer and Hepatic Dysfunction
33. Exploration of Patient-Related Barriers to Effective Cancer Pain Management in a Diverse Multicultural Developing Country
34. A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.
35. Living on the Frontline of COVID-19 in MCO And CMCO
36. Health‐related quality‐of‐life assessment of patients with solid tumors on immuno‐oncology therapies
37. Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes
38. Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients
39. A case of pleural thymoma presenting as bilateral pleural based mass
40. Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017
41. Oncologist-led BRCAcounselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes
42. Chylothorax and central vein thrombosis, an under‐recognized association: a case series
43. PP01.84 Tepotinib + Osimertinib in EGFR-mutant NSCLC with METAmplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
44. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer
45. The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer
46. An Asian multi-regional registry study of rare cancers: The MASTER KEY ASIA and MASTER KEY Japan projects.
47. Tepotinib + osimertinib for EGFR mutant (EGFR m) NSCLC with MET amplification (MET amp) after first-line (1L) osimertinib.
48. Effect of low-dose, short-course sunitinib (Su) on tumor vasculature and tumor blood flow for enhancement of chemotherapy efficacy in breast cancer.
49. EGFR Exon 20 Insertion A763-Y764insFQEA and Response to Erlotinib—Letter
50. Correlation of pharmacokinetics of CPT-11 in FOLFIRI with phenotyping of CYP3A4 and UGT1A1 activity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.